John Overdeck’s Alexion Pharmaceuticals ALXN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-57,783
| Closed | -$8.84M | – | 4788 |
|
|
2021
Q1 | $8.84M | Buy |
57,783
+41,179
| +248% | +$6.37M | 0.02% | 751 |
|
|
2020
Q4 | $2.59M | Buy |
16,604
+7,268
| +78% | +$934K | 0.01% | 1325 |
|
|
2020
Q3 | $1.07M | Sell |
9,336
-50,485
| -84% | -$5.45M | ﹤0.01% | 1708 |
|
|
2020
Q2 | $6.71M | Sell |
59,821
-297,071
| -83% | -$31.5M | 0.03% | 527 |
|
|
2020
Q1 | $32M | Sell |
356,892
-26,939
| -7% | -$2.64M | 0.26% | 64 |
|
|
2019
Q4 | $41.5M | Buy |
383,831
+381,415
| +15,787% | +$40.8M | 0.12% | 180 |
|
|
2019
Q3 | $237K | Sell |
2,416
-83,200
| -97% | -$9.38M | ﹤0.01% | 3103 |
|
|
2019
Q2 | $11.2M | Sell |
85,616
-24,776
| -22% | -$3.19M | 0.04% | 548 |
|
|
2019
Q1 | $14.9M | Sell |
110,392
-97,457
| -47% | -$12.1M | 0.05% | 507 |
|
|
2018
Q4 | $20.2M | Buy |
207,849
+135,166
| +186% | +$16M | 0.08% | 330 |
|
|
2018
Q3 | $10.1M | Sell |
72,683
-118,715
| -62% | -$14.9M | 0.03% | 640 |
|
|
2018
Q2 | $23.8M | Buy |
+191,398
| New | +$22.4M | 0.07% | 360 |
|
|
2017
Q4 | – | Sell |
-173,418
| Closed | -$21.1M | – | 3553 |
|
|
2017
Q3 | $24.3M | Buy |
173,418
+22,617
| +15% | +$3.07M | 0.09% | 286 |
|
|
2017
Q2 | $18.3M | Sell |
150,801
-278,619
| -65% | -$32.4M | 0.07% | 350 |
|
|
2017
Q1 | $52.1M | Buy |
+429,420
| New | +$55.4M | 0.18% | 149 |
|
|
2016
Q4 | – | Sell |
-388,550
| Closed | -$47.6M | – | 3637 |
|
|
2016
Q3 | $47.6M | Sell |
388,550
-397,966
| -51% | -$51.2M | 0.17% | 132 |
|
|
2016
Q2 | $91.8M | Buy |
786,516
+607,547
| +339% | +$86.2M | 0.39% | 51 |
|
|
2016
Q1 | $24.9M | Buy |
+178,969
| New | +$26.3M | 0.12% | 203 |
|
|
2015
Q4 | – | Sell |
-363,912
| Closed | -$63.6M | – | 3092 |
|
|
2015
Q3 | $56.9M | Buy |
363,912
+312,175
| +603% | +$56.9M | 0.29% | 96 |
|
|
2015
Q2 | $9.35M | Sell |
51,737
-172,728
| -77% | -$29.8M | 0.04% | 469 |
|
|
2015
Q1 | $38.9M | Buy |
224,465
+215,639
| +2,443% | +$39M | 0.18% | 150 |
|
|
2014
Q4 | $1.63M | Sell |
8,826
-26,921
| -75% | -$4.99M | 0.01% | 1121 |
|
|
2014
Q3 | $5.93M | Sell |
35,747
-19,737
| -36% | -$3.24M | 0.03% | 580 |
|
|
2014
Q2 | $8.67M | Sell |
55,484
-484,922
| -90% | -$76.6M | 0.04% | 529 |
|
|
2014
Q1 | $82.2M | Buy |
+540,406
| New | +$85.9M | 0.44% | 38 |
|
|
2013
Q4 | – | Sell |
-52,553
| Closed | -$6.11M | – | 2449 |
|
|
2013
Q3 | $6.11M | Sell |
52,553
-238,045
| -82% | -$26.1M | 0.04% | 477 |
|
|
2013
Q2 | $26.8M | Buy |
+290,598
| New | +$28M | 0.19% | 147 |
|
Other funds holding ALXN
FCM
HI
DKCM
PCM
UOC
John Overdeck's ALXN Position: Q2 2021 in Review
John Overdeck sold out of Alexion Pharmaceuticals (ALXN) in Q2 2021, closing a stake of 57,783 shares — an estimated $8.84M sold.
John Overdeck first reported a position in ALXN in Q2 2013 and held it in 27 quarters. The position peaked at $91.8M in Q2 2016. 708 funds tracked by Wall St. Rank hold ALXN as of Q2 2021.
- John Overdeck reported no remaining Alexion Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
- John Overdeck sold 57,783 Alexion Pharmaceuticals shares in Q2 2021, an estimated $8.84M.
- John Overdeck first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 27 quarters.
- John Overdeck's Alexion Pharmaceuticals position peaked at $91.8M in Q2 2016.
- 708 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2021.
Based on Two Sigma Investments's 13F filing for Q2 2021, filed 16 Aug 2021.